BiogenBIIB
BIIB
About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Employees: 7,605
0
Funds holding %
of 7,295 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
23% more repeat investments, than reductions
Existing positions increased: 324 | Existing positions reduced: 263
21% more first-time investments, than exits
New positions opened: 126 | Existing positions closed: 104
1% more funds holding
Funds holding: 855 [Q4 2024] → 861 (+6) [Q1 2025]
3.56% less ownership
Funds ownership: 90.14% [Q4 2024] → 86.58% (-3.56%) [Q1 2025]
14% less capital invested
Capital invested by funds: $20.1B [Q4 2024] → $17.3B (-$2.76B) [Q1 2025]
44% less call options, than puts
Call options by funds: $345M | Put options by funds: $621M
50% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
13%
downside
Avg. target
$176
33%
upside
High target
$255
93%
upside
12 analyst ratings
7 positive
58%
5 neutral
42%
0 negative
0%
Piper Sandler David Amsellem | 13%downside $115 | Neutral Reiterated | 12 Jun 2025 |
Wedbush Laura Chico | 9%downside $121 | Neutral Reiterated | 12 Jun 2025 |
Mizuho Salim Syed | 28%upside $169 | Outperform Maintained | 7 May 2025 |
JP Morgan Chris Schott | 32%upside $175 | Neutral Maintained | 5 May 2025 |
RBC Capital Brian Abrahams | 55%upside $205 | Outperform Maintained | 2 May 2025 |
Financial journalist opinion
Based on 6 articles about BIIB published over the past 30 days
Neutral
GlobeNewsWire
22 hours ago
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.
Neutral
Seeking Alpha
2 days ago
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
Neutral
GlobeNewsWire
1 week ago
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Positive
CNBC Television
2 weeks ago
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.
Neutral
GlobeNewsWire
2 weeks ago
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise
Neutral
Schaeffers Research
4 weeks ago
Outside Days Offer Intriguing Options Opportunity
Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX).
Neutral
Seeking Alpha
1 month ago
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Neutral
GlobeNewsWire
1 month ago
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal.
Negative
Zacks Investment Research
1 month ago
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
Neutral
Seeking Alpha
1 month ago
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priya Singhal - Head, Development Robin Kramer - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs Tim Anderson - Bank of America Chris Schott - JPMorgan Michael Yee - Jefferies Mike DiFiore - Evercore ISI Terence Flynn - Morgan Stanley Geoff Meacham - Citibank Operator Good morning. My name is Melinda, and I'll be your conference operator today.
Charts implemented using Lightweight Charts™